Samsung Biologics reports fourth quarter and fiscal year 2025 financial results
PR Newswire —
Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion Maintained momentum through consistent operational performance and robust client demand Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale INCHEON,...